Positron emission tomography in the management of non-small cell lung cancer (Q35684131)

9 August 2017

1 reference

title

Positron emission tomography in the management of non-small cell lung cancer (English)

1 reference

positron emission tomography

9 August 2017

1 reference

inferred from title

author name string

Johan F Vansteenkiste

series ordinal

1

1 reference

PubMed ID

15005293

9 August 2017

Sigrid G Stroobants

series ordinal

2

1 reference

PubMed ID

15005293

9 August 2017

language of work or name

1 reference

1 February 2004

1 reference

Hematology / Oncology Clinics of North America

9 August 2017

1 reference

9 August 2017

18

1 reference

9 August 2017

1

1 reference

9 August 2017

269-288

1 reference

The mechanism of accumulation of tumour-localising radiopharmaceuticals

9 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Phase II study of Taxol combined With ifosfamide and carboplatin in the treatment of stage IIIb-IV non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

[(18)F]FDG PET monitoring of tumour response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumour cell fraction?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

18F-2-deoxy-2-fluoro-D-glucose uptake into human tumor xenografts. Feasibility studies for cancer imaging with positron-emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

The noninvasive staging of non-small cell lung cancer: the guidelines.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Consensus report IASLC workshop Bruges, September 2002: pretreatment minimal staging for non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Incidence of local recurrence and second primary tumors in resected stage I lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Distribution of distant metastases from newly diagnosed non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Isolated adrenal masses in nonsmall-cell bronchogenic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Preoperative CT evaluation of adrenal glands in non-small cell bronchogenic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Non-small cell lung carcinoma adrenal metastases. Computed tomography and percutaneous needle biopsy in their diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Imaging of adrenal tumors using FDG PET: comparison of benign and malignant lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Detection of extrathoracic metastases by positron emission tomography in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Staging non-small cell lung cancer with whole-body PET.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Clinical evaluation of whole-body 18F-fluorodeoxyglucose positron emission tomography in the detection of liver metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Staging non-small cell lung cancer by whole-body positron emission tomographic imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Whole-body 18FDG positron emission tomography in the staging of non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Preoperative staging of non-small-cell lung cancer with positron-emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

The impact of fluorodeoxyglucose F 18 positron-emission tomography on the surgical staging of non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Additional Value of Whole-Body Fluorodeoxyglucose Positron Emission Tomography in the Detection of Distant Metastases of Non–Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

18-FDG positron emission tomography in the evaluation of malignant pleural diseases - a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

FDG PET of pleural effusions in patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Clinical role of F-18 fluorodeoxyglucose positron emission tomography imaging in patients with lung cancer and suspected malignant pleural effusion

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Value of computed tomography and mediastinoscopy in preoperative evaluation of mediastinal nodes in non-small cell lung cancer. A study of 569 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Mediastinal staging of non-small-cell lung cancer with positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Staging of the mediastinum: value of positron emission tomography imaging in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Mediastinal lymph node staging of non-small-cell lung cancer: a prospective comparison of computed tomography and positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer: a prospective analysis of 50 cases. Leuven Lung Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

FDG-PET scan in potentially operable non-small cell lung cancer: do anatometabolic PET-CT fusion images improve the localisation of regional lymph node metastases?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

PET, CT, and MRI with Combidex for mediastinal staging in non-small cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Improvement of non-small-cell lung cancer staging by means of positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Accuracy and clinical impact of mediastinal lymph node staging with FDG-PET imaging in potentially resectable lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Mediastinal lymph node involvement in potentially resectable lung cancer: comparison of CT, positron emission tomography, and endoscopic ultrasonography with and without fine-needle aspiration

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

The role of positron emission tomography with 18F-fluoro-2-deoxy-D-glucose in respiratory oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Metastases from non-small cell lung cancer: mediastinal staging in the 1990s--meta-analytic comparison of PET and CT.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Positron emission tomography in the diagnosis and staging of lung cancer: a systematic, quantitative review

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Significance of metastatic disease in subaortic lymph nodes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Survival and prognostic factors in resected N2 non-small cell lung cancer: a study of 140 cases. Leuven Lung Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Molecular abnormalities in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Hormonal treatment in advanced non-small cell lung cancer: fact or fiction?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Determination of the prognostic value of [(18)F]fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Dose-volume histogram and 3-D treatment planning evaluation of patients with pneumonitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Positron emission tomography in the pretreatment evaluation and follow-up of non-small cell lung cancer patients treated with radiotherapy: preliminary findings

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Multimodality nuclear medicine imaging in three-dimensional radiation treatment planning for lung cancer: challenges and prospects

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

The contribution of 18F-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

The impact of (18)FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small-cell lung carcinoma: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer: a prospective pilot study. The Leuven Lung Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Results of induction chemotherapy followed by surgical resection in patients with stage IIIA (N2) non-small cell lung cancer: the importance of the nodal down-staging after chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: A phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

A phase II trial testing gemcitabine as second-line chemotherapy for non small cell lung cancer. The European Lung Cancer Working Party. 101473.1044@compuserve.com

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET).

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Positron emission tomography for treatment evaluation and recurrence detection compared with CT in long-term follow-up cases of lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2-deoxy-D-glucose

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Value of FDG-PET in detecting residual or recurrent nonsmall cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Evaluation of 9-[(3-18F-fluoro-1-hydroxy-2-propoxy)methyl]guanine ([18F]-FHPG) in vitro and in vivo as a probe for PET imaging of gene incorporation and expression in tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Early changes in [18F]FLT uptake after chemotherapy: an experimental study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900152-7

7 January 2021

10.1016/S0889-8588(03)00152-7

Identifiers

DOI

1 reference

9 August 2017

1 reference

PubMed ID

15005293